These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography for Evaluating the Response to Neoadjuvant Chemotherapy in Advanced Esophageal Cancer.
    Author: Tani Y, Nakajima M, Kikuchi M, Ihara K, Muroi H, Takahashi M, Domeki Y, Okamoto K, Yamaguchi S, Sasaki K, Tsuchioka T, Sakamoto S, Kato H.
    Journal: Anticancer Res; 2016 Jan; 36(1):367-73. PubMed ID: 26722067.
    Abstract:
    BACKGROUND/AIM: The purpose of the present study was to improve the diagnostic precision of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) after neoadjuvant chemotherapy (NAC) in patients with advanced esophageal cancer. PATIENTS AND METHODS: Thirty patients underwent FDG-PET/CT before and after NAC. The maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV) were measured. Patients were divided into two pathological response groups: "responders" (grades 1b-3) or "non-responders" (grades 0-1a). RESULTS: Overall, 11 patients were responders. Significant differences were present for the post-NAC SUVmax (p=0.070), %decrease in SUVmax (p=0.017), post-NAC MTV (p=0.014), and %decrease in MTV (p=0.003). CONCLUSION: Receiver operating characteristic curve analysis showed that the %decrease in MTV of the primary tumor was the best indicator of response to NAC. We are currently striving to improve the accuracy of this assessment method.
    [Abstract] [Full Text] [Related] [New Search]